SLIDE 1
COMPANY SUMMARY BIO Boston 1x1 meeting
GENEURO ___________ NAME OF THE CEO Jesús MARTIN-GARCIA ADRESS 3 Chemin du Pré-Fleuri CH-1228 Plan-les-Ouates Geneva, Switzerland _____________________ EMAIL contact@geneuro.com www.geneuro.com MANAGEMENT TEAM CEO: Jesús Martin-Garcia CFO: Miguel Payró CMO: Robert Glanzman TARGETED MARKET ____________ MS, T1D, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), ALS LISTED COMPANY CREATION DATE April 2006
MISSION
GeNeuro is a clinical-stage biopharmaceutical company focused on stopping autoimmune and neurodegenerative diseases such as multiple sclerosis (MS) and type 1 diabetes (T1D) by neutralizing causal factors encoded by human endogenous retroviruses (HERV), which represent 8% of the human DNA.
TECHNOLOGY
Its most advanced therapeutic candidate, GNbAC1, is an antibody that neutralizes a pathogenic protein of the HERV-W family (pHERV-W Env) that has been identified as a potential causal factor in MS and T1D. GeNeuro communicated successful results of a Phase IIb in MS in March, and expects results of a Phase IIa in T1D in 3Q18.
COMPETITION
GeNeuro is the front runner in the HERV field, protected by 16 families of patents.
ALLIANCES/PARTNERSHIPS
€362 million partnership with Servier in 2014. This agreement relates solely to MS and does not cover the US market nor the applications of GeNeuro’s technology in other indications, for which all rights have been retained by GeNeuro
UPCOMING CATALYSTS
- New anti-pHERV antibodies (e.g. ALS, inflammatory psychosis)
- T1D Phase IIa results 3Q2018
- US IND & opening Phase II trial in Secondary Progressive MS patients
- Resolution of Servier’s option to license GNbAC1 in MS ex-US and ex-Japan